Rates of patient withdrawals from study by deprivation quintile in the Salford Lung Study (SLS) of COPD and SLS asthma (total study populations and SLS asthma inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy subset#)
| Deprivation quintile¶ | SLS COPD (n=2791) | SLS asthma (n=4218) | ICS/LABA therapy subset (n=2642) | ||||||
| Patients | FF/VI (n=1396) | UC (n=1395) | Patients | FF/VI (n=2105) | UC (n=2113) | Patients | FF/VI (n=1319) | UC (n=1323) | |
| 1 | 1453 | n=731 54 (7%) | n=722 53 (7%) | 855 | n=412 40 (10%) | n=443 37 (8%) | 551 | n=268 23 (9%) | n=283 18 (6%) |
| 2 | 601 | n=307 26 (8%) | n=294 14 (5%) | 834 | n=434 47 (11%) | n=400 43 (11%) | 526 | n=276 26 (9%) | n=250 29 (12%) |
| 3 | 391 | n=189 12 (6%) | n=202 15 (7%) | 856 | n=401 32 (8%) | n=455 38 (8%) | 551 | n=252 20 (8%) | n=299 26 (9%) |
| 4 | 209 | n=104 9 (9%) | n=105 7 (7%) | 831 | n=425 37 (9%) | n=406 30 (7%) | 511 | n=265 23 (9%) | n=246 18 (7%) |
| 5 | 137 | n=65 4 (6%) | n=72 3 (4%) | 842 | n=433 37 (9%) | n=409 24 (6%) | 503 | n=258 20 (8%) | n=245 14 (6%) |
Data are presented as n (%) who withdrew from the study. FF/VI: fluticasone furoate/vilanterol; UC: usual care. #: the SLS asthma ICS/LABA therapy subset comprised patients whose baseline maintenance therapy per randomisation stratification and pre-randomisation prescription was an ICS/LABA; ¶: where 1 is the most deprived and 5 is the least deprived.